Revisiting the Immune Frontier in Soft Tissue Sarcomas
Open Access
- 17 March 2026
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 28 (1)
Abstract
Purpose of Review: Soft tissue sarcomas (STS) comprise a heterogeneous group of mesenchymal malignancies with limited treatment options and poor outcomes in the advanced setting. Although immune checkpoint inhibitors have transformed the management of many solid tumors, their efficacy in STS has been modest and strongly histology dependent. This review aims to synthesize recent advances in immuno-oncology as applied to STS and to highlight emerging strategies that may overcome resistance and improve patient outcomes. Recent Findings: Thus far, clinically meaningful activity of immune checkpoint inhibitors has been identified select STS subtypes, including undifferentiated pleomorphic sarcoma, angiosarcoma, and alveolar soft part sarcoma. Combination approaches incorporating immune checkpoint inhibitors with chemotherapy, radiation, tyrosine kinase inhibitors, or novel immune modulators have shown enhanced antitumor activity in early-phase and randomized trials. In parallel, engineered T-cell therapies targeting cancer-testis antigens have emerged as a standard-of-care option in synovial sarcoma and are being expanded to other histologies. Finally, advances in tumor microenvironment characterization, including the role of tertiary lymphoid structures and myeloid modulation, are refining patient selection and informing rational trial design. Summary: Immunotherapy continues to reshape the therapeutic landscape of soft tissue sarcoma. While immune checkpoint blockade alone benefits only a subset of patients, rational combination strategies and cellular therapies offer promising avenues to broaden clinical efficacy. Continued integration of biomarker-driven approaches, translational correlative studies, and histology-specific trial designs will be essential to fully realize the potential of immunotherapy in STS.Keywords
This publication has 66 references indexed in Scilit:
- More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven TreatmentsAmerican Society of Clinical Oncology Educational Book, 2018
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trialsThe Lancet Oncology, 2018
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trialThe Lancet Oncology, 2017
- CDK4/6 inhibition triggers anti-tumour immunityNature, 2017
- Absence of Microsatellite Instability In Soft Tissue SarcomasPathobiology, 2015
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialThe Lancet Oncology, 2014
- NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcomaCancer, 2012
- Clear Cell Sarcoma of Soft TissueAmerican Journal of Surgical Pathology, 2008
- Differential sensitivity of liposarcoma subtypes to chemotherapyEuropean Journal of Cancer, 2005
- The cancer/testis genes: review, standardization, and commentary.2004